Floatz logo

CLEMASTIN

Multiple Sclerosis, Chronic Progressive

University of California, San FranciscoSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Multiple Sclerosis, Chronic Progressive cohort.

Asset / SponsorPhaseRating
D-thioctic acid
Rebecca Spain
Phase 2/3BB
Cyclophosphamide
Bruce Cree
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Centre Hospitalier de PAU
Phase 2B
Masitinib
AB Science
Phase 3B
Nurown Msc-Ntf Cells
Brainstorm-Cell Therapeutics
Phase 2B

View all 29 →

Same molecule, other indications

CLEMASTIN is also rated in:

relapsing-remitting multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →
multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
internuclear ophthalmoplegiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →